deltatrials
Unknown PHASE2 INTERVENTIONAL 1-arm NCT02943252

The Clinical Study of Apatinib Plus S1 for Patients With Advanced Non-squamous Head and Neck Cancer

PhaseⅡSingle-center, Open-label, Exploratory Clinical Study of Apatinib in Combination With S1 for the Patients With Advanced Non-squamous Head and Neck Cancer

Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Interventions Apatinib S1
Updated 6 times since 2017 Last updated: Oct 21, 2016 Started: Oct 31, 2016 Primary completion: Oct 31, 2019 Completion: Oct 31, 2021
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Head and Neck Neoplasms and is currently ongoing. Cancer Institute and Hospital, Chinese Academy of Medical Sciences leads this study, which shows 6 recorded versions since 2016 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Jan 2017 – ~Jun 2018 · 17 months · monthly snapshotRecruiting~Jun 2018 – ~Jan 2021 · 31 months · monthly snapshotRecruiting~Jan 2021 – ~Nov 2021 · 10 months · monthly snapshotRecruiting~Nov 2021 – ~Jul 2024 · 32 months · monthly snapshotUnknown Status~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotUnknown~Sep 2024 – present · 22 months · monthly snapshotUnknown

Change History

6 versions recorded
  1. Sep 2024 — Present [monthly]

    Unknown PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Unknown PHASE2

    Status: Unknown StatusUnknown

  3. Nov 2021 — Jul 2024 [monthly]

    Unknown Status PHASE2

    Status: RecruitingUnknown Status

  4. Jan 2021 — Nov 2021 [monthly]

    Recruiting PHASE2

  5. Jun 2018 — Jan 2021 [monthly]

    Recruiting PHASE2

Show 1 earlier version
  1. Jan 2017 — Jun 2018 [monthly]

    Recruiting PHASE2

    First recorded

Oct 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Data source: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations